745 Thurlow Street
Vancouver, BC V6E 0C5
Full Time Employees:
|Dr. Allen Warren Davidoff Ph.D.||Founder, CEO, Pres & Director||192k||N/A||1960|
|Mr. Amar Keshri||Chief Financial Officer||N/A||N/A||1978|
|Nick Rigopoulos||Director of Communications||N/A||N/A||N/A|
|Dr. David Sans M.B.A., Ph.D.||Director of Corp. Devel.||N/A||N/A||N/A|
|Dr. Stephen Haworth M.D., MRCP||Chief Medical Officer||N/A||N/A||N/A|
|Ms. Charlotte May||Corp. Sec.||N/A||N/A||N/A|
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, hypertension, insulin resistance, and diabetic nephropathy. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is headquartered in Vancouver, Canada.
XORTX Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.